Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study

被引:0
|
作者
Zoghbi, Marianne [1 ]
Jabbour, Elias [1 ]
Haddad, Fadi [1 ]
Short, Nicholas James [1 ]
Senapati, Jayastu [1 ]
Macaron, Walid [1 ]
Nasnas, Cedric Christophe [1 ]
Nasr, Lewis Fady [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Wierda, William G. [1 ]
Borthakur, Gautam [1 ]
Bravo, Guillermo Montalban [1 ]
Ravandi, Farhad [1 ]
Garcia-Manero, Guillermo [1 ]
Kadia, Tapan M. [1 ]
Chien, Kelly Sharon [1 ]
Thankachan, Jennifer [1 ]
Garris, Rebecca [1 ]
Kantarjian, Hagop M. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e19039
引用
收藏
页数:1
相关论文
共 50 条
  • [1] A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
    Venugopal, Sangeetha
    Kantarjian, Hagop
    Short, Nicholas J.
    Thompson, Philip A.
    Pemmaraju, Naveen
    Jain, Nitin
    Wierda, William G.
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Ohanian, Maro
    Chien, Kelly S.
    Thankachan, Jennifer
    Nwakanme, Benjamin
    Garris, Rebecca
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [2] A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
    Short, Nicholas J.
    Jabbour, Elias
    Jain, Nitin
    Senapati, Jayastu
    Nasr, Lewis
    Haddad, Fadi G.
    Li, Zhenhua
    Hsiao, Yu-Chih
    Yang, Jun J.
    Pemmaraju, Naveen
    Ohanian, Maro
    Wierda, William G.
    Montalban-Bravo, Guillermo
    Borthakur, Gautam
    Han, Lina
    Xiao, Lianchun
    Huang, Xuelin
    Abramova, Regina
    Zhao, Min
    Garris, Rebecca
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop
    BLOOD ADVANCES, 2024, 8 (04) : 909 - 915
  • [3] Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sasaki, Koji
    Jabbour, Elias J.
    O'Brien, Susan M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Burger, Jan A.
    Pemmaraju, Naveen
    Alvarado, Yesid
    Daver, Naval G.
    Jain, Nitin
    Konopleva, Marina
    Champlin, Richard E.
    Khouri, Issa F.
    Kebriaei, Partow
    Marin, David
    DiNardo, Courtney D.
    Estrov, Zeev
    Takahashi, Koichi
    Short, Nicholas J.
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2016, 128 (22)
  • [4] Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Takahashi, Koichi
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge E.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [5] A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
    Jain, Nitin
    Stevenson, Kristen E.
    Winer, Eric S.
    Garcia, Jacqueline S.
    Stone, Richard M.
    Jabbour, Elias
    Ravandi, Farhad
    Stewart, Jeremy M.
    Legg, Dean R.
    Kantarjian, Hagop M.
    Neuberg, Donna S.
    Letai, Anthony G.
    Konopleva, Marina Y.
    DeAngelo, Daniel J.
    BLOOD, 2019, 134
  • [6] Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
    Jabbour, Elias
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Short, Nicholas J.
    Thomas, Deborah
    Sasaki, Koji
    Rytting, Michael
    Jain, Nitin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard
    Marin, David
    Kadia, Tapan
    Cortes, Jorge
    Estrov, Zeev
    Takahashi, Koichi
    Patel, Yogin
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan
    Kantarjian, Hagop
    JAMA ONCOLOGY, 2018, 4 (02) : 230 - 234
  • [7] Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)
    O'Brien, S. M.
    Aulitzky, W.
    Ben Yehuda, D.
    Lister, J.
    Schiller, G. J.
    Selter, K.
    Smith, S. E.
    Stock, W.
    Silverman, J. A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
    Nasnas, Cedric Christophe
    Jabbour, Elias
    Haddad, Fadi
    Short, Nicholas James
    Macaron, Walid
    Zoghbi, Marianne
    Nasr, Lewis Fady
    Jain, Nitin
    Almanza, Emmanuel
    Sasaki, Koji
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wang, Sa A.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
    Assi, Rita
    Kantarjian, Hagop M.
    Ravandi, Farhad
    O'Brien, Susan Mary
    Kebriaei, Partow
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Khouri, Issa F.
    Champlin, Richard E.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Jain, Nitin
    Konopleva, Marina
    Khouri, Rita
    Estrov, Zeev
    Takahashi, Koichi
    Sasaki, Koji
    Jacob, Jovitta
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Short, Nicholas J.
    Kebriaei, Partow
    Huang, Xuelin
    Rytting, Michael E.
    Jain, Nitin
    Konopleva, Marina Y.
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Estrov, Zeev E.
    Takahashi, Koichi
    Mace, Morgan
    Khouri, Maria
    Nasnas, Patrice
    Jacob, Jovitta
    Garris, Rebecca E.
    Jabbour, Elias J.
    BLOOD, 2018, 132